By Victor Talon • Wednesday, November 11, 2026
The Defense Department published notice Tuesday removing WuXi AppTec from its Section 1260H list of Chinese military companies. The notice says the action complies with an August 7 preliminary injunction from the federal district court in Washington. It also preserves the possibility of relisting the company on additional or supplementary grounds, making this a specific administrative action rather than a permanent promise about future national-security decisions.
The newly published record identifies the designation at issue as the one appearing in the June 10 list. The court order barred the department from enforcing or otherwise giving effect to that designation. Tuesday’s notice, dated November 5 and filed for publication November 9, supplies an official public update to the list. Keeping those dates separate matters: the injunction, the department’s document and its Federal Register publication are different steps in the same dispute.
Chief Judge James Boasberg’s August opinion explains the legal basis for preliminary relief. He found WuXi likely to succeed in arguing that the designation was arbitrary and capricious under the Administrative Procedure Act, and concluded that the other injunction factors favored relief. That is an assessment supporting an interim order. It should not be described as a final merits judgment resolving every possible basis for government scrutiny of the company.
The opinion also explains why designation has practical weight. Congress has attached procurement and funding consequences to the list, and the court described evidence of damaged commercial relationships after publication. WuXi provides services to pharmaceutical and life-science customers. The dispute therefore reaches beyond a label on a government website: customers considering research and manufacturing relationships must understand which designation is operative and which legal proceeding produced the change.
WuXi’s leadership has publicly disputed the designation and welcomed the preliminary injunction. Its account calls the designation erroneous and expresses confidence in the continuing litigation. Those are the company’s positions. The court’s analysis and the department’s notice provide separate records against which to read them. Together they show both an active challenge to the administrative record and the government’s formal response to the interim judicial restriction.
For national-security oversight, the next meaningful developments would be a further court order, a revised administrative decision or a new listing supported by additional grounds. Tuesday’s notice does not establish that all biotechnology-related government restrictions have disappeared, and it does not forecast the litigation’s ultimate result. It does establish that this company has been removed from this list in compliance with the cited injunction. That narrower conclusion gives readers a reliable starting point for tracking what comes next.
Sources
FOLLOW THE ENTIRE CREW
Daily reporting and newsroom updates from FrontPage Crew.
